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Abstract
The archipelago gene (ago) encodes the F-box specificity subunit of an SCF(skp-cullin-f box) ubiquitin ligase that inhibits cell proliferation in
Drosophila melanogaster and suppresses tumorigenesis in mammals. ago limits mitotic activity by targeting cell cycle and cell growth proteins
for ubiquitin-dependent degradation, but the diverse developmental roles of other F-box proteins suggests that it is likely to have additional protein
targets. Here we show that ago is required for the post-mitotic shaping of the Drosophila embryonic tracheal system, and that it acts in this tissue
by targeting the Trachealess (Trh) protein, a conserved bHLH-PAS transcription factor. ago restricts Trh levels in vivo and antagonizes
transcription of the breathless FGF receptor, a known target of Trh in the tracheal system. At a molecular level, the Ago protein binds Trh and is
required for proteasome-dependent elimination of Trh in response to expression of the Dysfusion protein. ago mutations that elevate Trh levels in
vivo are defective in binding forms of Trh found in Dysfusion-positive cells. These data identify a novel function for the ago ubiquitin-ligase in
tracheal morphogenesis via Trh and its target breathless, and suggest that ago has distinct functions in mitotic and post-mitotic cells that influence
its role in development and disease.
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The morphogenesis of branched networks of cells with a
single, fused lumen plays an important role in the development
of many metazoan organs, including the vertebrate lungs,
vasculature, kidneys, and mammary glands. The cellular
architecture of these mammalian organs is quite similar to
tubular structures in simpler metazoans, suggesting that the
molecular and cellular mechanisms underlying the process of
branching morphogenesis are conserved. In the fruit fly Dro-
sophila melanogaster, tubular morphogenesis underlies forma-
tion of the tracheal system, a network of interconnected tubes
that duct air throughout the developing organism. The complete
embryonic tracheal network is composed of approximately
1600 polarized epithelial cells that originate in early embry-
ogenesis as 20 ectodermal placodes distributed along either side⁎ Corresponding author.
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contains approximately 20 cells, which undergo two rounds of
cell division, exit the cell cycle, and complete the subsequent
stages of invagination and tracheogenesis without further cell
division or cell death. Following invagination, primary
branches bud from the tracheal sac and form a continuous
lumen within each placode (Lubarsky and Krasnow, 2003). The
pattern of placode branching is segmentally repeated and under
fixed genetic control (Samakovlis et al., 1996). Budded
branches extend toward their target tissues by a process of
cell migration and cell extension, and subsequent fusion
between adjacent tracheal metameres at later stages of
embryogenesis produces a continuous, open tubular system.
Forward genetic screens for mutations that disrupt tracheal
development have revealed a central role for fibroblast growth
factor (FGF) signaling in promoting the post-mitotic cell
migration and extension of the embryonic tracheal arbor
(reviewed in Metzger and Krasnow, 1999). The central
components of the Drosophila FGF pathway are encoded by
the breathless (btl) (Klambt et al., 1992) and branchless (bnl)
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receptor and an FGF-like secreted ligand respectively. The role
of this receptor/ligand pair in controlling tracheal outgrowth is
based upon a simple model in which the restricted expression of
bnl in cells outside the tracheal placode represents a directional
cue for the migration of btl-expressing cells within the tracheal
placode. Initial induction of btl transcription within tracheal
cells depends upon the trachealess (trh) gene, which encodes a
basic helix–loop–helix Per/Arnt/Sim (bHLH-PAS) domain
transcription factor (Isaac and Andrew, 1996; Kuo et al.,
1996; Ohshiro and Saigo, 1997; Wilk et al., 1996) most closely
homologous to the mammalian NPAS1 and NPAS3 proteins
(Brunskill et al., 1999; Zhou et al., 1997). Mutation of any one
of these core components – btl, bnl, or trh – produces a failure
of tracheal branching. Phenotypic analysis of these and other
tracheogenesis genes has shown that Btl/FGF signaling is used
to promote successive rounds of primary and secondary tracheal
branching during embryonic Drosophila development
(reviewed in Ghabrial et al., 2003). A similar role has been
proposed for the FGF pathway in controlling the branching
morphogenesis of tubes in the mammalian lung (Min et al.,
1998).
In addition to a positive role in tracheal outgrowth,
experimental evidence indicates that inappropriately timed
Btl/FGF signaling can also impair tracheal development. First,
in the course of normal development btl expression is not
constant in tracheal cells, but oscillates: initially btl mRNA
rises in all placode cells at stages 10–12 preceding primary
branch formation, subsequently falls during late stage 12/early
stage 13, and is re-initiated in a restricted set of cells that
define sites of secondary branching at late stage 13/early
stage14. Unlike early btl expression, this second wave is
dependent upon a bnl-dependent feedback loop (Ohshiro et
al., 2002; Ohshiro and Saigo, 1997). Second, ectopic
activation of Btl, either by mutational inactivation of the btl
inhibitor abnormal wing disc (awd) (Dammai et al., 2003), or
by constitutive expression of bnl (Sutherland et al., 1996) or
btl (this study and Lee et al., 1996), interferes with directed
cell migration in the trachea. Similarly, expression of activated
Ras or btl perturbs the ability of tracheal cells to form proper
branching patterns in larval development (Cabernard and
Affolter, 2005). These observations have led to the hypothesis
that spatial and quantitative restriction of Btl activity is
necessary to permit normal patterns of tracheal cell migration
and fusion (Lee et al., 1996). While many genes that modulate
Btl/FGF signaling have been identified, it is likely that other
as yet unrecognized mechanisms are required to restrict Btl/
FGF signaling to specific times and places in the developing
organism.
Here we identify archipelago (ago), a gene known primarily
for its role in cell proliferation control, as a component of the
genetic circuitry that patterns the post-mitotic development of
the embryonic tracheal system. ago encodes an F-box/WD-
repeat protein that recruits target proteins to an SCF-type E3
Ub-ligase for subsequent poly-ubiquitination and proteolytic
destruction. ago limits the division and growth of Drosophila
eye epithelial cells by targeting the G1/S regulator Cyclin E anddMyc, the fruit fly ortholog of the human c-Myc proto-
oncogene, for proteasome-mediated degradation (Moberg et al.,
2001, 2004). A highly conserved mammalian ago ortholog
(variously termed Fbw7, Fbxw7, hAgo, hCDC4, or hSel-10)
also targets Cyclin E and c-Myc and is a mutational target in a
rapidly expanding array of human cancers (Balakrishnan et al.,
2007; Bredel et al., 2005; Calhoun et al., 2003; Hagedorn et al.,
2007; Malyukova et al., 2007; Mao et al., 2004; Maser et al.,
2007; Minella et al., 2007; O'Neil et al., 2007; Rajagopalan et
al., 2004; Thompson et al., 2007). Our current data indicate that
ago is required for tracheal morphogenesis via a previously
unrecognized target, the Trachealess (Trh) transcription factor.
We find that ago mutant embryos contain excess Trh protein
and ectopically express the btl gene, a known Trh target. Alleles
of ago exhibit strong genetic interactions with trh and other
known tracheogenesis genes, and the Ago protein is able to bind
the Trh protein and regulate its proteasomal turnover via a
mechanism that involves a third factor, the bHLH-PAS protein
Dysfusion (Dys; Jiang and Crews, 2003). Collectively, these
data reveal a previously unappreciated developmental function
for the ago tumor suppressor in the embryonic tracheal system,
and identify the Trh transcription factor as a target of Ago in this
process.
Materials and methods
Stocks, genetics, and statistics
The ago alleles ago1 and ago3 have been previously described (Moberg
et al., 2001). Unless indicated, analysis was performed on ago1/ago3 trans-
heterozygotes. Full-length ago and agoΔF, a version of ago lacking the core F-
box domain (Moberg et al., 2004), were cloned as PCR products into the EcoRI
site of the pUAST vector (Brand and Perrimon, 1993) and used to generate UAS-
ago and UAS-agoΔF stocks (D. Rennie, Massachusetts General Hospital
Transgenic Drosophila Core). Other alleles used in this study were: btldev1,
btlEY01638, trh10512, awdj2A4, Df(3L)Exel9000 and esg-lacZ (all from Blooming-
ton Drosophila Stock Center), 1-eve-1 (Perrimon et al., 1991), btl-Gal4 (Shiga
et al., 1996), UAS-trh (Jin et al., 2001), FRT80B, UAS-CycE, UAS-dMyc.
Crosses involving the temperature-sensitive UAS-Pros261 and UAS-Prosβ21
transgenes (gift of J. Belote) were performed at 21 °C. Embryos were genotyped
using the TM6B, P{iab-2(1.7)lacZ}6B, Tb1 and CyO, P{elav-lacZ.H}YH2 ‘blue’
balancers, or the TM3, P{Gal4-twi.G}2.3, P{UAS-2xEGFP}AH2.3, Sb1Ser1
balancer. Statistical comparisons were made using Student's t-test.
Embryo immunohistochemistry and antibodies
Embryos were staged and fixed in 37% formaldehyde-saturated heptane,
devitellinized in methanol and stored in ethanol at 4 °C. These samples were
rehydrated and washed in PBS with 0.05% Triton-X 100 (PBSTx), blocked in
5% milk powder/5% NGS in PBSTx, and incubated with the following primary
antibodies: mouse anti-Tango (1:5, Developmental Studies Hybridoma Bank;
DSHB), rat anti-Trh (1:200) a gift of D. Andrew (Henderson et al., 1999), mouse
mAb2A12 (1:5; DSHB), rabbit anti-β-Gal (1:300; Cappel), guinea pig anti-full
length Ago (1:2500; Pocono Rabbit Farm & Laboratory), rat anti-Dys (1:200)
and rabbit anti-Dys (1:800) both a gift of S. Crews (Jiang and Crews, 2003).
Secondary antibodies conjugated to HRP, AP, Cy3, and Cy5 were used as
recommended (Jackson ImmunoResearch). Embryos from w1118 and ago1/TM3,
P{Gal4-twi.G}2.3, P{UAS-2xEGFP}AH2.3, Sb1Ser1 strains were collected at
stages 13/14 and sorted by absence of GFP fluorescence. Extracts were prepared
in sample buffer containing DTT and resolved on 7.5% SDS-PAGE prior to
Western blotting with rat anti-Trh (1:2000), or anti-β-tubulin (1:2000; Santa
Cruz Biotechnology). Anti-HA and anti-Flag antibodies (Sigma) were used
according to manufacturer's instructions.
Table 1
ago1 and ago3 behave as null alleles in tracheogenesis
Genotype DT breaks (%) n=
FRT80B 3 a 61
ago1/ago3 46 85
ago1/Exel9000 39 57
ago3/Exel9000 38 42
Percent penetrance of the dorsal trunk ‘break’ phenotype in embryos of the
indicated genotypes.
a pb0.01 compared to ago1/3.
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RNA in situ hybridization was performed as described (Tautz, 2000).
Briefly, embryos were fixed in 1.5% formaldehyde (in 0.1 M HEPES, pH 6.9,
2 mM MgSO4, 1 mM EGTA)-saturated heptane, devitellinized, and stored in
methanol at −20 °C. Embryos were washed in PBS with 0.1% Tween 20, treated
with 15 μg/ml Proteinase K for 2 min, and post-fixed with 4% paraformalde-
hyde. Riboprobe hybridization and subsequent immunohistochemistry were
performed as described (Tautz, 2000). Sense and anti-sense digoxigenin (DIG)-
labeled riboprobes were synthesized from a 1 kb PCR fragment amplified from
btl cDNA and visualized by the anti-DIG-AP antibody (1:2000; Roche).
Plasmids and molecular biology
pMT-HA-ago expression plasmids have been described previously (Moberg
et al., 2004). pMT-Flag-trh was generated by cloning the full-length trh ORF
(Open Biosystems) into the pMT vector as an N-terminally Flag-tagged PCR
product. The pACT-HA-dys plasmid (gift of S. Crews) contains an N-terminally
tagged version of the dys ORF under the control of a constitutively active
fragment of the actin promoter. Transfected S2 cells were induced by the
addition of 0.5 mM CuSO4 for 6 h prior lysis in buffer containing 0.5M KCl,
0.1% NP-40, 35% glycerol, 10 mM HEPES pH 7.0, 5 mM MgCl2, 0.5 mM
EDTA pH 8.0, 25 mM NaF, 1 mM Na2VO4, 1 mM DTT supplemented with
protease inhibitors (Complete™ Protease Inhibitor Cocktail; Roche). Where
indicated, 50 μMMG132 (Calbiochem) was added 6 h prior to harvesting cells.
Lysates were analyzed directly by immunoblot (IB), or diluted in immunopre-
cipitation (IP) buffer and subject to IP/IB analysis as described previously
(Moberg et al., 2004).
Results
ago has role in embryonic tracheal development
Analysis of the growth restrictive role of ago in proliferating
larval imaginal disc cells has provided an excellent model to
understand the tumor suppressive properties of ago mammalianFig. 1. Ago is widely expressed during embryogenesis. Lateral views of FRT80B co
uniformly during the cellularization (A), and germ-band extended (B) and retract
concentrated in the CNS during late embryogenesis (D). In this and all further figur
staining in an embryo homozygous for the Df(3L)Exel9000 deletion, which removeorthologs. However, the Ago protein is widely expressed in the
early embryo (Fig. 1) and mutations that disrupt it lead to
embryonic death (Moberg et al., 2001). Intercrossing the ago1
or ago3 alleles (respectively encoding a C-terminal truncation
in the WD-repeat/substrate-binding domain and a G1131E
missense mutation in the 4th WD repeat; Moberg et al., 2001)
produces trans-heterozygous mutant embryos that develop
through all embryonic stages but fail to hatch as L1 larvae (data
not shown), suggesting lethality occurs during late embryogen-
esis. The severity of this and other phenotypes (see below) in
homozygous or heteroallelic mutant animals is indistinguish-
able from those carrying either allele in trans to a chromosomal
deficiency that removes the ago locus (Table 1; Df(3L)
Exel9000), indicating that ago1 and ago3 are either null or
strong loss-of-function alleles. Considered together, these
observations indicate that ago may have as yet unappreciated
roles in early development.
The earliest morphological defects in ago zygotic mutant
embryos are observed in the developing trachea visualized with
the anti-lumen antibody mAb2A12 (Figs. 2C–F). This analysis
reveals two major defects in tracheal branching patterns of agontrol embryos stained with Ago-specific antiserum. Ago expression is detected
ed (C) stages, but is not detectable in pole cells (arrow in panel A). Ago is
es, embryos are shown anterior left and dorsal up (unless indicated). Anti-Ago
s the ago gene (E).
Fig. 2. ago is required for tracheogenesis. Lateral views of FRT80B (A) or ago embryos (C, F) stained with mAb2A12 to visualize the tracheal. Major tracheal
branches are indicated in panel A: dorsal trunk (DT), lateral trunk (LT), transverse connectives (TC), dorsal branches (DB), ganglionic branches (GB), and visceral
branches (VB). agomutants display interruptions in the lumen of the DT (arrowhead in panel C) and LT (arrows in panel C). 1-eve-1 (B) or 1-eve-1, ago (D) embryos
stained with anti-β-Gal (green) to mark tracheal cells and mAb2A12 to mark the lumen (red). The DT lumen interruptions in ago mutant embryos correspond to
physical breaks in the DT (arrowhead in panel D). Dorsal views of FRT80B (E, left panel) and ago (E, right panel) embryos stained with mAb2A12. ago mutant
embryos show defects in DB fusion (arrow) as well as DB misrouting (arrowhead). The DT lumens in ago mutant embryos display a convolution defect (F). Staining
of esg-lacZ (G) and esg-lacZ;ago (H) embryos with anti-Trh (brown) and anti-β-Gal (purple). Arrows in H mark fusion cells in adjacent placodes. Arrowhead
indicates a break in the dorsal trunk. Panels B and D are reconstructions of serial sections.
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continuity of the tracheal lumen (Figs. 2C–E). The breaks occur
throughout the tracheal system and are prominent in the dorsal
trunk (DT; Figs. 2C, D, arrowheads), the lateral truck (LT; Fig.
2C, arrows), and between dorsal branches of opposing tracheal
placodes (DB; Fig. 2E, arrow). What appears to be a misrouting
phenotype is also observed in the dorsal branches (Fig. 2E,
arrowhead) and ganglionic branches (data not shown). Approx-
imately 70% of all ago mutant embryos show combinations of
these break or misrouting effects. The second prominent
tracheal phenotype (occurring in ∼25% of all ago mutant
embryos) is excess lumen convolution throughout the primary
and secondary branches (Fig. 2F). This combined spectrum of
breaks, apparent misrouting, and convolution indicates that
ago is required for normal development of the tracheal
system. Moreover, the absence of any accompanying defects
in the major morphogenetic events of embryogenesis (NTM
and KHM, unpublished) suggests that these phenotypes reflecta requirement for ago in the trachea, rather than as a second-
ary effect of a more general developmental role outside this
tissue.
The DT break phenotype occurs in almost half of all ago
mutant embryos (46%, n=85) with an average of 1.2±0.09
breaks among those that show the phenotype (n=39). On a per
fusion event basis, this corresponds to a greater than 15-fold
increase in the rate of defective interplacode fusion events in
ago mutants compared to control embryos (Supplemental Fig.
1). Due to the prevalence of this phenotype, DT morphogenesis
was selected as a system in which to characterize the role of ago
in the developing tracheal system. To investigate the cellular
architecture of DT breaks in ago mutant embryos, the 1-eve-1
enhancer trap line, which carries a lacZ insertion in the trh gene
and expresses β-galactosidase (β-gal) in every tracheal cell
(Perrimon et al., 1991; Wilk et al., 1996), was placed in the wild
type and ago mutant backgrounds (Figs. 2B, D). Anti-β-gal
staining of these embryos reveals that lumenal gaps detected
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of adjacent tracheal placodes (Fig. 2D, arrowhead). Interplacode
fusion along the DT is normally dependent upon specialized
‘fusion cells’, which are specified 2 per placode by a Notch-
dependent process (Ikeya and Hayashi, 1999). At the appro-
priate stage, one migrates anteriorly and the other posteriorly to
meet with fusion cells coming from adjacent placodes. Thus, the
gaps between adjacent DT placodes in ago mutant embryos
suggest either that ago is necessary for proper fusion cell
specification, or that ago mutations impair fusion cell migration
and/or fusion. To test these hypotheses, DT fusion cells were
visualized in wild type and ago mutant stage 15 embryos (Figs.
2G, H) using the fusion cell-specific enhancer trap escargot
(esg)-lacZ (Tanaka-Matakatsu et al., 1996). Analysis of wild
type embryos in which the process of DT fusion is complete
shows esg-lacZ expression (purple nuclei; Fig. 2G) in a pair of
adjacent fusion cell nuclei. In ago mutant embryos, pairs of
esg-lacZ positive fusion cells flank regions of DT breaks (Fig.
2H, arrows mark fusion cell nuclei, arrowhead marks gap in
DT). Analysis of a second fusion cell marker, the Dysfusion
protein (Jiang and Crews, 2003), gives similar results (data not
shown). Thus ago DT breaks are not associated with altered
fusion cell numbers but rather a failure of agomutant DT fusion
cells to fuse with adjacent placodes. This differs significantly
from tracheal phenotypes elicited by btlGal4-driven over-
expression the putative Ago target Notch (Fryer et al., 2004;
Gupta-Rossi et al., 2001; Oberg et al., 2001; Tsunematsu et al.,Fig. 3. ago acts within tracheal cells and interacts with Btl/FGF signaling component
agoΔF (A), btl (B), or trh (C) phenocopies the agoDT break phenotype (arrowheads)
the indicated genotypes. (D) btl-Gal4-driven expression of agoΔF (yellow), btl (red),
is suppressed by expression of wild type ago in the btl-Gal4 domain (yellow), or
**pb0.01 compared to FRT80B (D) or ago (E).2004; Wu et al., 2001), which results in a complete loss of
fusion cells (Ikeya and Hayashi, 1999). The lack of an effect on
fusion cell number also contrasts with ago proliferative
phenotypes in imaginal discs (Moberg et al., 2001, 2004). To
further confirm this, we measured total cell number in wild type
and agomutant DTs using an anti-Tango antiserum (Sonnenfeld
et al., 1997). This analysis shows that these genotypes have
approximately equal numbers of nuclei per DT segment
(wt=16.7±0.4, n=6; ago=17.0±0.7, n=9). Thus, the primary
effect of ago loss in the DT is not on cell number, but rather on
the ability of cells to follow the normal developmental program
of cell migration and fusion.
Because Ago protein is expressed uniformly in tracheal and
non-tracheal cells (Supplemental Fig. 1), the requirement for
ago in the DT could be indicative of a cell-autonomous role
for ago in tracheal cells or it might reflect a non-cell
autonomous role for ago outside the developing placode in,
for example, the mesodermal ‘bridge cells’ necessary for DT
fusion (Wolf and Schuh, 2000). To determine the site of ago
action, a wild type UAS-ago transgene and a dominant-negative
UAS-agoΔF transgene were expressed specifically in the
developing tracheal system using the btl-Gal4 driver (Shiga et
al., 1996). btl-Gal4-driven expression of wild type ago in an
ago1/ago3 mutant background significantly reduces the fre-
quency of DT breaks (Fig. 3E, compare yellow and blue bars)
and the other observed tracheal phenotypes in ago mutant
embryos (data not shown). Moreover, btl-Gal4-driven expres-s. mAb2A12 staining of stage 15 embryos (A–C). btl-Gal4-driven expression of
. (D, E) Quantitative summary of the DT break phenotype in stage 15 embryos of
or trh (green) phenocopies ago mutations (blue). (E) The agomutant phenotype
by reducing the genetic dosage of either btl (red) or trh (green). *pb0.05 and
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wild type tracheal cells is sufficient to produce DT breaks at
similar penetrance as zygotic deficiency for ago (Table 2 and
Figs. 3A, D). The agoΔF allele carries an internal deletion of
the core F-box domain (Moberg et al., 2004), and is defective in
ubiquitin-dependent protein degradation. While these data do
not rule out a secondary role for ago in non-tracheal cells, they
do argue that ago plays a required role in a protein degradation
pathway that is active in embryonic tracheal cells.
ago acts upstream of trachealess and breathless
Because loss of ago leads to excess activity of proteins
normally regulated by Ago-dependent degradation (Moberg et
al., 2001, 2004), known Ago target proteins were tested for their
ability to reproduce ago mutant tracheal phenotypes when
expressed in the btl-Gal4 domain. Expression of cycE and
dMyc, two targets of Ago in imaginal disc cells, does not
reproduce the ago mutant tracheal phenotype (Table 2),
suggesting that ago controls tracheal morphogenesis via a
novel target. Significantly, btl-Gal4-driven expression of either
trh or its downstream target btl produces DT breaks of similar
penetrance and expressivity as ago mutations (Figs. 3B–D),
and also leads to lumen convolution (data not shown).
Moreover, loss-of-function alleles of trh (trh10512; Isaac and
Andrew, 1996) or btl (btldev1; Kennison and Tamkun, 1988) are
each able to dominantly suppress ago tracheal phenotypes (Fig.
3E, green and red bars, respectively). The sensitivity of ago
phenotypes to the genetic dosage of trh and btl suggests that
ago may inhibit Trh in the developing trachea. To test the
effect ago mutations on Trh protein levels, wild type and ago
mutant embryos were stained with a Trh-specific antiserum
(Fig. 4). Compared to control embryos, ago mutant embryos
contain significantly higher levels of Trh in all tracheal cells
(Figs. 4A, B). This effect is also evident in immunoblot blot
analysis of Trh levels in ago and control embryos (Fig. 4C). Trh
protein is normally detected in the nuclei of all tracheal cells,
but is specifically eliminated from fusion cells, including those
of the dorsal trunk, by a mechanism that requires fusion-cell-
specific expression of the Dysfusion (Dys) bHLH-PAS domain
transcription factor (Jiang and Crews, 2003). In addition to
limiting the steady-state levels of Trh in all tracheal cells, ago is
also required for the Dys-stimulated elimination of Trh thatTable 2
ago is phenocopied by ectopic expression of FGF pathway members, but not the
Ago targets Cyclin E and dMyc
Genotype DT breaks (%) n=
FRT80B 3 a 61
ago1/ago3 46 85
btl-Gal4:UAS-agoΔF 39 56
btl-Gal4:UAS-trh 28 56
btl-Gal4:btlEY01638 31 53
btl-Gal4:UAS-CycE 18 a 64
btl-Gal4:UAS-dMyc 3 a 66
Percent penetrance of the dorsal trunk ‘break’ phenotype in embryos of the
indicated genotypes.
a pb0.01 compared to ago1/3.occurs specifically in fusion cells (Figs. 4D, E). Expression of
Dys occurs normally in ago embryos (see middle panel, Fig.
4E), but in these same cells Trh levels do not decline, and DT
fusion cells with high levels of both Dys and Trh are readily
observed (Fig. 4E, arrows). Thus, the antagonistic genetic
interaction between ago and trh in the tracheal system appears
to have its basis in a requirement for ago in limiting the steady-
state levels of Trh in all tracheal cells, and in the specific
elimination of Trh from fusion cells.
The effect of ago alleles on Trh levels, and the genetic
interaction between ago and the Trh target gene btl, indicates
that ectopic Trh-driven transcription of btlmay contribute to the
ago phenotype. The developmental regulation of the btl
promoter is complex and involves inputs from a number of
factors other than Trh, including the transcriptional activators
pointed (Klambt, 1993; Ohshiro et al., 2002) and ventral
veinless (Anderson et al., 1996), and the transcriptional
repressors anterior open (Ohshiro et al., 2002) and spalt
(Kuhnlein and Schuh, 1996). To test whether the failure to
down-regulate Trh in ago mutant cells is sufficient to cause
misexpression of btl, RNA in situ hybridization analysis was
performed using a btl-specific anti-sense RNA probe. In stage
15 control embryos, levels of btl mRNA expression in the DT
do not rise above the background signal obtained with btl anti-
sense (Fig. 5A) or sense (data not shown) probes. In contrast,
pairs of btl-positive cells are evident along the DT of all ago
mutant embryos (Fig. 5B, see arrows). The location and pattern
of this ectopic btl expression suggest that these paired cells
correspond to fusion cells, and that failure to eliminate Trh in
these cells leads to ectopic btl transcription. The lack of a
similar effect in the remaining ago mutant tracheal cells
suggests that excess Trh must collaborate with fusion-cell-
specific factors in order to drive ectopic btl transcription.
In view of the requirement for btl in the ago phenotype (see
Table 3 and Fig. 3B) and the finding that excess Btl activity
disrupts DT architecture (see Fig. 3B and Dammai et al., 2003;
Lee et al., 1996; Ohshiro et al., 2002), the effect of ago on btl
suggests that Trh-driven transcriptional deregulation of btl is an
important element of ago DT phenotype. However, while the
molecular effect of ago inactivation on Trh and btl is fully
penetrant, the resultant morphological defects in tracheal
structure are not. This might be expected if the elevated levels
of Trh and btl reach a threshold that is sufficient to perturb
tracheal development in a portion of embryos, but that other
pathways acting redundantly to ago are able to enforce the
developmental down-regulation of the Btl pathway. If so, then
ago mutations might be predicted to sensitize the tracheal
system to other mutations that increase Btl activity by non-
transcriptional mechanisms. To test this, a loss-of-function
allele of the abnormal wing discs gene (awdj2A4; Spradling et
al., 1999), which encodes a factor that promotes the endocytic
down-regulation of the Btl receptor in embryonic tracheal cells
(Dammai et al., 2003), was assayed for its ability to enhance the
ago tracheal phenotype (Figs. 5C, D). Reducing awd gene
dosage by half in ago mutant animals strongly enhances both
the penetrance (from 46% of embryos to greater than 80% of
embryos; see Fig. 5D, Table 4, and Supplemental Fig. 1) of the
Fig. 4. ago regulates Trh levels and is required for Trh elimination in tracheal fusion cells. Anti-Trh staining in ago/TM6B, P{iab-2(1.7)lacZ}6B, Tb1 (A) and ago1/
ago3 (B) embryos. (C) Anti-Trh (top) and anti-β-tub (bottom; loading control) Western blot analysis of stage 13/14 control and ago mutant embryos (10 embryos/
lane). FRT80B (D) and ago (E) embryos stained with anti-Trh (green, right panel) and anti-Dys (red, center panel) to mark fusion cells. Trh levels are reduced in Dys-
positive wild type fusion cells (arrows in panel D), but not in Dys-positive ago mutant fusion cells (arrows in panel E).
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embryos (from 1.2±0.09 breaks/embryo, n=39 to 6.1±0.95
breaks/embryo, n=41). These ago/ago,awd/+ embryos also
show a much more severe disruption of the entire tracheal
system than do ago mutants alone (compare Figs. 5C to 2C).
Moreover, a significant fraction of ago/+,awd/+ trans-hetero-
zygous embryos show DT breaks. In view of the data indicating
that ago and awd are both upstream of btl via transcriptional
and endocytic mechanisms, respectively, these strong synthetic
effects suggest that ago and awd mutations collaborate to
deregulate Btl in the developing tracheal system.
Ago binds Trh and restricts Trh levels in cells
The ability of agomutations to elevate Trh levels in vivo and
to uncouple Trh levels from the rise in Dys indicates that Ago
acts downstream of Dys as part of the mechanism that
eliminates Trh protein in fusion cells. To examine interactions
between Ago and Trh more closely, epitope tagged versions of
these proteins were co-expressed in S2 cells (Figs. 6A, B).
Analysis shows that while Trh accumulates to high levels when
expressed in S2 cells, co-expression of Ago results in a subtle
but reproducible reduction (∼20% by density quantitation;
Photoshop) in Trh levels (Fig. 6A, top panel, lanes 1–2). This
effect appears to parallel the negative effect ago has on Trh
levels in non-fusion cells that do not normally express Dys (see
Fig. 4B). However, when Ago and Trh are co-expressed with
Dys, the in vivo trigger of Trh down-regulation, Trh levels drop
dramatically (Fig. 6A, top panel, lane 3) in much the same way
Trh levels drop in response to Dys expression in vivo (see Fig.
4D and in Jiang and Crews, 2003). The parallel decline in the
level of Ago is consistent with findings that other F-boxproteins are destabilized by reductions in the level of their
substrates (Li et al., 2004) and mimics the relationship between
dMyc and Ago stability in S2 cells (Moberg et al., 2004).
Examination of the effect of Dys on Trh reveals that expression
of dys is sufficient to decrease Trh levels in the absence of
exogenous Ago (Fig. 6B, lane 3). However, as is observed in
embryonic tracheal cells (Fig. 4E), this effect of Dys in S2 cells
still requires endogenous Ago since RNAi-knockdown of ago
is sufficient to block it (Fig. 6B, lane 4). Addition of the
proteasome inhibitor MG132 also blocks the Ago/Dys-
stimulated decline in Trh levels in S2 cells (Fig. 6B, lane 5).
In parallel to these in vitro effects, btl-Gal4-mediated expres-
sion of dominant-negative alleles of the proteasome subunits
Pros26 and Prosβ2 (Belote and Fortier, 2002) is sufficient to
phenocopy ago alleles and block down-regulation of Trh in
embryonic fusion cells (Fig. 6C). From these data, it appears
that Trh is a target of a proteasomal degradation pathway in
embryonic tracheal cells and in cultured S2 cells, and that in
both cases the mechanism underlying this effect requires ago
and can be greatly potentiated by co-expression of dys.
The genetic and functional interactions between ago and trh
suggest that their encoded products may physically interact in
cells. To test this hypothesis, Flag-tagged Trh and HA-tagged
versions of either wild type Ago, the AgoΔF dominant negative
protein, or the truncated Ago1 protein (lacking an intact WD
domain) were expressed in S2 cells and analyzed by co-
immunoprecipitation (Fig. 7). Wild type Ago, Ago1, and
AgoΔF are all recovered in anti-Flag immunoprecipitates
(Fig. 7A, lanes 2–4) and reciprocally, Flag-Trh is readily
detected in anti-HA immunoprecipitates from cells expressing
HA-AgoΔF (Fig. 7B). Thus, in the absence of exogenous Dys,
Trh is able to interact with all three forms of Ago in S2 cells,
Fig. 5. btl transcription is deregulated in ago mutant embryos. RNA in situ hybridization of FRT80B (A) and ago (B) stage 16 embryos with btl anti-sense probe.
Arrows in B denote btl-expressing cells. (C) Lateral view of a stage 15 ago;awd−/+ embryo stained with mAb2A12 showing enhanced expressivity of the ago mutant
phenotype. (D) Quantitative summary of the DT break phenotype in stage 15 embryos of the indicated genotypes showing interactions between ago and awd.
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Trh regulation in vivo. Co-expression of Dys with these
combinations of Ago and Trh, and simultaneously blocking
proteasome function so as to stabilize the Ago–Trh complex,
induces a significant change the nature of the Ago–Trh
interaction (Fig. 7C). The form of Trh protein that accumulates
in MG132-treated, Dys-expressing cells remains competent to
bind wild type Ago but fails to interact with the WD-truncation
mutant Ago1 (Fig. 7C, top panel, compare lanes 3 and 5). Thus,
an ago mutation that deregulates Trh levels in vivo is defective
in binding to the form of Trh normally targeted for proteasome-
dependent elimination in Dys-expressing fusion cells. Con-
sidered together, these data show that Ago and Trh can bind
specifically to one another, and that this interaction is required
to limit Trh levels in vivo.
Discussion
The biological properties of individual F-box proteins are to
a large degree determined by their repertoire of target proteins.
In the case of the Drosophila Ago F-box protein, failure to
degrade these targets promotes excess proliferation of imaginalTable 3
The ago phenotype is dominantly suppressed by alleles of FGF pathway
members, and is rescued by tracheal-cell-specific expression of Ago
Genotype DT breaks (%) n=
FRT80B 3∗∗ 61
ago1/ago3 46 85
ago1/ago3;btl-Gal4:UAS-ago 15∗∗ 73
ago1/ago3;trh10512/+ 31∗ 135
ago1/ago3;btldev1/+ 26∗∗ 99
Percent penetrance of the dorsal trunk ‘break’ phenotype in embryos of the
indicated genotypes. ∗pb0.05 and ∗∗pb0.01 compared to ago1/3.disc cells. This observation has led to the identification of
Cyclin E and Myc proteins as ago targets (Moberg et al., 2001,
2004). However, the broad pattern of Ago expression in the
embryo suggests that it might regulate distinct processes and
targets in other cell types. In view of the rapidly growing body
of work showing that inactivation of human ago/Fbw7 is a
common event in a variety of cancers (e.g. Malyukova et al.,
2007; O'Neil et al., 2007; Thompson et al., 2007), identification
of these targets may provide important insight into the biology
of cancers lacking ago function.
Here we show that Drosophila Ago is required for the post-
mitotic morphogenesis of the embryonic tracheal system and
that this requirement is due, at least in part, to the ability of
Ago to bind directly to a previously unrecognized target, the
Trh transcription factor, and stimulate its proteasomal degrada-
tion. This ago degradation mechanism appears to fulfill
different regulatory roles in different populations of tracheal
cells. In non-fusion tracheal cells, ago is required to limit
overall levels of Trh, which is normally expressed at moderate
levels throughout the tracheal system. In tracheal fusion cells,
the ago degradation mechanism appears to be strongly
potentiated by an unidentified signal generated by Dys, such
that Trh is completely eliminated from Dys-expressing cells.Table 4
ago dominantly interacts with an allele of the Btl antagonist awd
Genotype DT breaks (%) n=
FRT80B 3 61
ago3/+ 7 56
awdj2A4/+ 17∗ 42
ago3,awdj2A4/+ 30∗∗ 33
ago3,awdj2A4/ago1 83∗∗ 52
Penetrance of indicated phenotypes in embryos of the indicated genotypes.
∗pb0.05 and ∗∗pb0.01 compared to FRT80B.
Fig. 6. Ago regulates Trh levels in S2 cells and during embryogenesis. Quantification of the steady-state levels of either Trh and Ago by immunoprecipitation-
immunoblot (IP/IB) from S2 cells transfected with the indicated plasmids. (A) Trh accumulate to detectable levels in S2 cells (lane 1), are slightly reduced in the
presence of Ago (lane 2), and are greatly reduced after co-expression of Ago and Dys (lane 3). (B) The Dys-mediated reduction in Trh levels occurs in the absence of
transfected Ago (lane 3) but is blocked by ago dsRNA treatment (lane 4) or by blocking proteasome function with MG-132 (lane 5). (C) Inhibition of proteasome
function also stabilizes Trh levels in vivo. btl-Gal4:UAS-Pros261,UAS-Prosβ21 embryos stained with anti-Trh (green, right panel) and anti-Dys (red, center panel)
show a failure to down-regulate Trh levels in fusion cells (arrows).
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on trh gene dosage argues that that elevated Trh levels are
primarily responsible for branching defects that occur in ago
zygotic mutant embryos. In support of this, persistent Trh
expression is also observed in ago mutant fusion cells in other
tracheal branches (NTM and KHM, unpublished observation).
This novel role for Ago in tracheal development is supported
by the independent finding that homozygosity for a genomic
deletion containing the ago locus is associated with cellFig. 7. Physical interaction between Ago and Trh. IP/IB analysis from S2 cells exp
recovered in anti-Flag precipitates (A) and that Trh is reciprocally recovered in ant
treated cells expressing the indicated cDNAs (C) shows that Trh is bound equally well
that in Dys-positive cells Trh is bound only by wild type Ago (top panel, lane 3) but n
Loading controls for Ago (middle panel) and Trh (bottom panel) are shown.migration defects in embryonic tracheal metameres (Myat
et al., 2005).
Many important developmental events are controlled by
multiple mechanisms that collaborate to regulate a key step in
the process. This somewhat redundant control insulates the
process from defects in any single pathway, such that major
defects only occur when multiple control mechanisms are
blocked. The observation that the effect of ago mutations on
Trh and btl levels is completely penetrant, but the resultingressing the indicated cDNAs shows that wild type Ago, AgoΔF, and Ago1 are
i-HA precipitates from cells expressing AgoΔF (B). IP/IB analysis of MG132-
by Ago (top panel, lane 2) and Ago1 (top panel, lane 4) in the absence of Dys, but
ot the Ago1 mutant (top panel, lane 5) that is defective in Trh regulation in vivo.
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acts redundantly to ago to control tracheal development. The
strong, dominant enhancement of the ago phenotype by a
mutation in the awd gene fits very well into a model in which
multiple pathways are responsible for the precisely timed
down-regulation of the Breathless/FGF pathway: ago attenu-
ates btl transcription by degrading Trh, awd lowers levels of
Btl protein on the cell surface by promoting its endocytic
internalization (Dammai et al., 2003), and other pathways act
independently to control expression of the FGF ligand
branchless in non-tracheal cells (Merabet et al., 2005; Suther-
land et al., 1996). Thus, the incomplete penetrance of the ago
phenotype is not indicative of an insignificant role for the gene
in tracheal development, but rather may indicate that the tra-
cheal system uses multiple mechanisms to redundantly control a
key step in its development.
The Ago WD repeat region binds Cyclin E and dMyc, and
the current work demonstrates that it also binds Trh. Broadly,
the Ago–Trh interaction is quite similar to interactions with
Cyclin E and dMyc: it is required for the down-regulation of
substrate levels in vivo, and its disruption elevates levels of
substrate that then drive downstream phenotypes. For substrates
like Myc, site-specific phosphorylation generates a motif that
binds to the Ago WD-region and stimulates rapid, SCF-
mediated protein turnover of the target protein (reviewed in
Minella and Clurman, 2005). In contrast, the data here suggest
that Trh can physically interact with Ago in two distinct
configurations: one that does not require an intact WD-domain
and a second WD-dependent mode of binding. The observation
that the Ago1 allele can participate in the first complex but not
the second and is defective in Trh regulation in vivo, suggests
that like other Ago targets, WD-dependent binding is associated
with rapid Trh turnover. Expression of Dys appears to shift the
balance in favor of this second mode of binding. Combined with
the genetic and phenotypic data implicating ago as an in vivo
regulator of Trh activity, these molecular data support a model
in which Ago can bind to Trh in the absence of Dys and
inefficiently stimulate Trh turnover by a WD-dependent
mechanism. This inefficient mechanism may be responsible
for the fairly mild increase in Trh levels observed in all ago
mutant dorsal trunk cells. However, in the presence of Dys, the
efficiency of Trh turnover in DT fusion cells is enhanced to the
degree that the entire pool of Trh is rapidly eliminated.
Interestingly, the correlate of this hypothesis – that ectopic
expression of dys in non-fusion cells should be sufficient to
trigger down-regulation of endogenous Trh – was confirmed in
a recent study (Jiang and Crews, 2006).
The nature of the Dys-generated signal responsible for this
effect is not currently known. Precedent with other Ago targets
suggests that it may involve Trh phosphorylation (Fryer et al.,
2004; Koepp et al., 2001; Nateri et al., 2004; Sundqvist et al.,
2005; Wei et al., 2005; Welcker et al., 2003, 2004; Yada et al.,
2004; Ye et al., 2004). Recent work on the mammalian ago
ortholog Fbw7 has shown that interactions with substrates can
also be modulated by interaction with accessory factors (Punga
et al., 2006), or by conformational changes in the substrate
driven by the isomerization of proline residues within the Ago/Fbw7 binding motif (van Drogen et al., 2006). Proline
isomerization has been implicated in the degradation of
mammalian c-Myc (Yeh et al., 2004), but such mechanisms
are not currently known to play a role in the degradation of
either Myc or bHLH-PAS proteins in Drosophila. An important
goal of future studies will be to determine if any of these types
of mechanisms are involved in Dys-induced Trh degradation in
tracheal cells.
The requirement for ago in tracheal cells suggests that the
consequences of ago loss vary considerably depending on the
proliferative state of the cells, their location within the
organism, and their developmental stage. ago mutant clones
in the mitotically active larval eye disc show no evidence of
excessive Trh levels or deregulated Btl/FGF signaling (NTM
and KHM, unpublished) and conversely, ago zygotic mutant
trachea do not display ‘extra cell’ defects similar to those
observed in the eye. The origins of this tissue specificity are
currently not clear, although it might simply reflect the
differential expression patterns of Ago targets in various mitotic
and post-mitotic cell populations. There is currently no evidence
that the mammalian Trh homologs NPAS-1 and NPAS-3 are
degraded by an Ago/Fbw7-dependent mechanism in mamma-
lian cells. However, the finding that Fbw7 knock-out mouse
embryos display defects in vascular development (Tetzlaff et al.,
2004; Tsunematsu et al., 2004) seems to indicate that the Fbw7
ligase may also target proteins involved in tubular morphogen-
esis, and intriguingly both NPAS1 and NPAS3 have been linked
either to this process (Levesque et al., 2007) or to the
transcriptional control of FGFR genes (Pieper et al., 2005). It
has been suggested that the Fbw7 vascular defects arise due to
Notch misregulation. However, since FGF signaling is known
to control branching morphogenesis of the mammalian
vasculature and lung (Min et al., 1998; Walgenbach et al.,
1995), the data presented here raise the possibility that vascular
phenotypes in Fbw7 knock-out mouse embryos may also reflect
the deregulation of developmental pathways that control
branching morphogenesis via mammalian homologs of trh
and btl.
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